DOI: https://doi.org/10.25305/unj.59044

The experimental study of metformin’s antitumor action in rats with brain glioma

Nikolay Lisianyi, Antonina Klyuchnikova, Oleksandr Lisianyi, Vera Semenova, Lyudmila Belska

Abstract


Introduction. Metformin, known as medicine for diabetes mellitus treatment, today is widely studied in oncology as drug for suppressing growth of different malignant tumors in experiments on animals.

Materials and methods. Metformin’s untitumor effect was studied on rats with glioma 101.8, treated with metformin or it’s combination with chemomedicines cisplatin or doxorubicin. The duration of animals’ life with brain glioma and it’s average rate in each group of rats were determined.

Results. The direct and combined influence of metformin on rats’ brain tumor was studied in experiment. It was determined that metformin in doses 50–150 mg/kg not influence on the growth of brain glioma. Metformin an injection with cisplatin or doxorubicin more often suppressed glioma’s growth then used separately.

Conclusion. On the base of experiments’ results analysis the use of metformin is recommended in neurooncology clinic during malignant gliomas treatment.


Keywords


brain glioma; metformin; cisplatin; doxorubicin; experiment

References


1. Dowling R, Zakikhani M, Fantus I, Pollak M, Sonenberg N. Metformin Inhibits Mammalian Target of Rapamycin Dependent Translation Initiation in Breast Cancer Cells. Cancer Research. 2007;67(22):10804-10812. [CrossRef] [PubMed]

2. Zakikhani M, Dowling R, Fantus I, Sonenberg N, Pollak M. Metformin Is an AMP Kinase-Dependent Growth Inhibitor for Breast Cancer Cells. Cancer Research. 2006;66(21):10269-10273. [CrossRef] [PubMed]

3. Sahra I, Laurent K, Loubat A et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008;27(25):3576-3586. [CrossRef] [PubMed]

4. Buzzai M, Jones R, Amaravadi R et al. Systemic Treatment with the Antidiabetic Drug Metformin Selectively Impairs p53-Deficient Tumor Cell Growth. Cancer Research. 2007;67(14):6745-6752. [CrossRef] [PubMed]

5. Isakovic A, Harhaji L, Stevanovic D et al. Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci. 2007;64(10):1290-1302. [CrossRef] [PubMed]

6. Gotlieb W, Saumet J, Beauchamp M et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecologic Oncology. 2008;110(2):246-250. [CrossRef] [PubMed]

7. Hirsch H, Iliopoulos D, Tsichlis P, Struhl K. Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission. Cancer Research. 2009;69(19):7507-7511. [CrossRef] [PubMed]

8. Liu B, Fan Z, Edgerton S et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009;8(13):2031-2040. [CrossRef] [PubMed]

9. Dowling R, Goodwin P, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Medicine. 2011;9(1):33. [CrossRef] [PubMed]

10. Belfiore A, Frasca F. IGF and Insulin Receptor Signaling in Breast Cancer. J Mammary Gland Biol Neoplasia. 2008;13(4):381-406. [CrossRef] [PubMed]

11. Saydah S. Abnormal Glucose Tolerance and the Risk of Cancer Death in the United States. American Journal of Epidemiology. 2003;157(12):1092-1100. [CrossRef] [PubMed]

12. Lipscombe L, Goodwin P, Zinman B, McLaughlin J, Hux J. Diabetes mellitus and breast cancer: a retrospective population-based cohort study. Breast Cancer Res Treat. 2006;98(3):349-356. [CrossRef] [PubMed]

13. Soritau O, Tomuleasa C, Aldea M, Petrushev B, Susman S, Gheban D, Ioani H, Cosis A, Brie I, Irimie A, Kacso G, Florian IS. Metformin plus temozolomide-based chemotherapy as adjuvant treatment for WHO grade III and IV malignant gliomas. J BUON. 2011 Apr-Jun;16(2):282-9. [PubMed]

14. Lisianyi N, Belska L, Klyuchnikova A. Іmmunomodulаtive and antitumor effect of celandine’s preparations on brain tumors. Ukrainian Neurosurgical Journal. 2011;(1):23-29. Ukrainian. [Abstract/Full Text]

15. Ben Sahra I, Le Marchand-Brustel Y, Tanti J, Bost F. Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug?. Molecular Cancer Therapeutics. 2010;9(5):1092-1099. [CrossRef] [PubMed]


GOST Style Citations


1.  Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells / R.J. Dowling, M. Zakikhani, I.G. Fantus [et al.] // Cancer Res. — 2007. — V.67. — P.10804–10812.

2.  Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells / M. Zakikhani, R. Dowling, I.G. Fantus [et al.] // Cancer Res. — 2006. — V.66. — P.10269–10273.

3.  The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level / I. Ben Sahra, K. Laurent, A. Loubat [et al.] // Oncogene. — 2008. — V.27. — P.3576–3586.

4.  Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth / M. Buzzai, R.G. Jones, R.K. Amaravadi [et al.] // Cancer Res. — 2007. — V.67. — P.6745–6752.

5.  Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis / A. Isakovic, L. Harhaji, D. Stevanovic [et al.] // Cell. Mol. Life Sci. — 2007. — V.64. — P.1290–1302.

6.  In vitro metformin anti-neoplastic activity in epithelial ovarian cancer / W.H. Gotlieb, J. Saumet, M.C. Beauchamp [et al.] // Gynecol. Oncol. — 2008. — V.110. — P.246–250.

7.  Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission / H.A. Hirsch, D. Iliopoulos, P.N. Tsichlis, K. Struhl // Cancer Res. — 2009. — V.69. — P.7507–7511.

8.  Metformin induces unique biological and molecular responses in triple negative breast cancer cells / B. Liu, Z. Fan, S.M. Edgerton [et al.] // Cell. Cycle J. — 2009. — V.8. — P.2031–2040.

9.  Understanding the benefit of metformin use in cancer treatment BMC / J.O. Ryan, I. Dowling, J. Pamela [et al.] // Med. J. — 2011. — V.9. — P.33–43.

10.       Belfiore A. IGF and insulin receptor signaling in breast cancer / A. Belfiore, F. Frasca // Mamm. Gland. Biol. Neoplas. J. — 2008. — V.13. — P.381–406.

11.       Abnormal glucose tolerance and the risk of cancer death in the United States / S.H. Saydah, C.M. Loria, M.S. Eberhardt, F.L. Brancati // Am. J. Epidemiol. — 2003. — V.157. — P.1092–1100.

12.       Diabetes mellitus and breast cancer, a retrospective population-based cohort study / L.L. Lipscombe, P.J. Goodwin, B. Zinman [et al.] // Breast Cancer Res. Treat. — 2006. — V.98. — P.349–356.

13.       Metformin plus temozolomide-based chemotherapy as adjuvant treatment for WHO grade III and IV malignant gliomas / O. Soritau, C. Tomuleasa, M. Aldea [et al.] // J. BUON. — 2011. — V.16, N2. — P.282–289.

14.       Лісяний М.І. Імуномодулююча та протипухлина дія препаратів чистотіла на пухлини головного мозку / М.І. Лісяний, Л.М. Бєльська, А.І. Ключникова // Укр. нейрохірург. журн. — 2011. — №1. — С.23–28.

15.       Metformin in сancer therapy: A new perspective for an old antidiabetic drug? / I.B. Sahra, B.Y. Le Marchand, J.F. Tanti [et al.] // Mol. Cancer Ther. — 2010. — V.9. — P.1092–1099.





Copyright (c) 2012 Nikolay Lisianyi, Antonina Klyuchnikova, Oleksandr Lisianyi, Vera Semenova, Lyudmila Belska

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.